100%, being less reliant on more CRs or partnerships in which we have to accept unfavourable terms are key benefits of having a revenue-generating product while we continue to develop our own.
We have very promising products under development and a high calibre board who knows how to take them through trials to market. Having cashflow to allow us choice and time in negotiating sales or partnerships puts us as a company in a much more favourable position than many.
There are plenty of research companies who have a product for commercialisation but few who are in a strong position to maximise the early value of its sale or licencing through a strong negotiating position.
100%, being less reliant on more CRs or partnerships in which we...
-
- There are more pages in this discussion • 7,048 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add BOT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
42.0¢ |
Change
-0.005(1.18%) |
Mkt cap ! $761.8M | |||
| Open | High | Low | Value | Volume |
| 43.0¢ | 44.5¢ | 41.5¢ | $2.435M | 5.697M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 20 | 819538 | 41.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 42.0¢ | 29052 | 2 |
View Market Depth
| Last trade - 16.10pm 13/09/2024 (20 minute delay) ? |
| BOT (ASX) Chart |